Report generated from Joint Formulary provided by FormularyComplete (www.pharmpress.com). Accessed 06 04 2017

TA Title Formulary Status Section TA Link Annotation Number

1.1 Dyspepsia and gastro-oesophageal ALUMINIUM reflux disease->1.1.1 Antacids and None HYDROXIDE simeticone->Aluminium- and magnesium-containing antacids

1.1 Dyspepsia and gastro-oesophageal reflux disease->1.1.1 Antacids and Aluminium-only Specialist simeticone->Aluminium- and preparations knowledge drugs magnesium-containing antacids->ALUMINIUM HYDROXIDE

1.1 Dyspepsia and gastro-oesophageal reflux disease->1.1.1 Antacids and Specialist simeticone->Aluminium- and Alu-Cap® knowledge drugs magnesium-containing antacids->ALUMINIUM HYDROXIDE->Aluminium-only preparations

1.1 Dyspepsia and gastro-oesophageal reflux disease->1.1.1 Antacids and Joint formulary Co-magaldrox simeticone->Aluminium- and choice magnesium-containing antacids->ALUMINIUM HYDROXIDE

1.1 Dyspepsia and gastro-oesophageal reflux disease->1.1.1 Antacids and Joint formulary simeticone->Aluminium- and Maalox® choice magnesium-containing antacids->ALUMINIUM HYDROXIDE->Co-magaldrox

1.1 Dyspepsia and gastro-oesophageal reflux disease->1.1.1 Antacids and Joint formulary simeticone->Aluminium- and Mucogel® choice magnesium-containing antacids->ALUMINIUM HYDROXIDE->Co-magaldrox 1.1 Dyspepsia and gastro-oesophageal MAGNESIUM Not approved for reflux disease->1.1.1 Antacids and CARBONATE prescribing simeticone->Aluminium- and magnesium-containing antacids

1.1 Dyspepsia and gastro-oesophageal reflux disease->1.1.1 Antacids and Aromatic Magnesium Not approved for simeticone->Aluminium- and Carbonate Mixture, BP prescribing magnesium-containing antacids->MAGNESIUM CARBONATE

1.1 Dyspepsia and gastro-oesophageal MAGNESIUM Hospital only reflux disease->1.1.1 Antacids and TRISILICATE prescribing simeticone->Aluminium- and magnesium-containing antacids

1.1 Dyspepsia and gastro-oesophageal reflux disease->1.1.1 Antacids and Magnesium Trisilicate Hospital only simeticone->Aluminium- and Tablets, Compound, BP prescribing magnesium-containing antacids->MAGNESIUM TRISILICATE

1.1 Dyspepsia and gastro-oesophageal reflux disease->1.1.1 Antacids and Magnesium Trisilicate Hospital only simeticone->Aluminium- and Mixture, BP prescribing magnesium-containing antacids->MAGNESIUM TRISILICATE

1.1 Dyspepsia and gastro-oesophageal Aluminium-magnesium Not approved for reflux disease->1.1.1 Antacids and complexes prescribing simeticone

1.1 Dyspepsia and gastro-oesophageal Not approved for reflux disease->1.1.1 Antacids and HYDROTALCITE prescribing simeticone->Aluminium-magnesium complexes

1.1 Dyspepsia and gastro-oesophageal Not approved for reflux disease->1.1.1 Antacids and With simeticone prescribing simeticone->Aluminium-magnesium complexes->HYDROTALCITE

1.1 Dyspepsia and gastro-oesophageal reflux disease->1.1.1 Antacids and Not approved for Altacite Plus® simeticone->Aluminium-magnesium prescribing complexes->HYDROTALCITE->With simeticone 1.1 Dyspepsia and gastro-oesophageal Antacid preparations Not approved for reflux disease->1.1.1 Antacids and containing simeticone prescribing simeticone

1.1 Dyspepsia and gastro-oesophageal Not approved for reflux disease->1.1.1 Antacids and Altacite Plus® prescribing simeticone->Antacid preparations containing simeticone

1.1 Dyspepsia and gastro-oesophageal Not approved for reflux disease->1.1.1 Antacids and Maalox Plus® prescribing simeticone->Antacid preparations containing simeticone

1.1 Dyspepsia and gastro-oesophageal Hospital only Simeticone alone reflux disease->1.1.1 Antacids and prescribing simeticone

1.1 Dyspepsia and gastro-oesophageal Not approved for Dentinox® reflux disease->1.1.1 Antacids and prescribing simeticone->Simeticone alone

1.1 Dyspepsia and gastro-oesophageal Hospital only Infacol® reflux disease->1.1.1 Antacids and prescribing simeticone->Simeticone alone

1.1 Dyspepsia and gastro-oesophageal reflux disease->1.1.2 Compound alginates Not approved for Acidex® and proprietary indigestion prescribing preparations->Alginate raft-forming oral suspensions

1.1 Dyspepsia and gastro-oesophageal reflux disease->1.1.2 Compound alginates Joint formulary Gaviscon® and proprietary indigestion choice preparations->Alginate raft-forming oral suspensions

1.1 Dyspepsia and gastro-oesophageal reflux disease->1.1.2 Compound alginates Joint formulary Peptac® and proprietary indigestion choice preparations->Alginate raft-forming oral suspensions 1.1 Dyspepsia and gastro-oesophageal reflux disease->1.1.2 Compound alginates Joint formulary Gastrocote® and proprietary indigestion choice preparations->Other compound alginate preparations

1.1 Dyspepsia and gastro-oesophageal reflux disease->1.1.2 Compound alginates Joint formulary Gaviscon® Advance and proprietary indigestion choice preparations->Other compound alginate preparations

1.1 Dyspepsia and gastro-oesophageal reflux disease->1.1.2 Compound alginates Joint formulary Gaviscon Infant® and proprietary indigestion choice preparations->Other compound alginate preparations

Not approved for 1.2 Antispasmodics and other drugs altering ATROPINE SULFATE prescribing gut motility->Antimuscarinics

1.2 Antispasmodics and other drugs altering Not approved for Atropine gut motility->Antimuscarinics->ATROPINE prescribing SULFATE

DICYCLOVERINE 1.2 Antispasmodics and other drugs altering None HYDROCHLORIDE gut motility->Antimuscarinics

1.2 Antispasmodics and other drugs altering Joint formulary gut Dicycloverine choice motility->Antimuscarinics->DICYCLOVERINE HYDROCHLORIDE

1.2 Antispasmodics and other drugs altering Compound Not approved for gut preparations prescribing motility->Antimuscarinics->DICYCLOVERINE HYDROCHLORIDE

1.2 Antispasmodics and other drugs altering Not approved for gut Kolanticon® prescribing motility->Antimuscarinics->DICYCLOVERINE HYDROCHLORIDE->Compound preparations

HYOSCINE Joint formulary 1.2 Antispasmodics and other drugs altering Parenteral hyoscine butylbromide has not been approved for prescribing. BUTYLBROMIDE choice gut motility->Antimuscarinics 1.2 Antispasmodics and other drugs altering Joint formulary Buscopan® gut motility->Antimuscarinics->HYOSCINE Parenteral hyoscine butylbromide has not been approved for prescribing. choice BUTYLBROMIDE

PROPANTHELINE Hospital only 1.2 Antispasmodics and other drugs altering BROMIDE prescribing gut motility->Antimuscarinics

1.2 Antispasmodics and other drugs altering Hospital only gut Pro-Banthine® prescribing motility->Antimuscarinics->PROPANTHELINE BROMIDE

Joint formulary 1.2 Antispasmodics and other drugs altering ALVERINE CITRATE choice gut motility->Other antispasmodics

1.2 Antispasmodics and other drugs altering Not approved for Spasmonal® gut motility->Other prescribing antispasmodics->ALVERINE CITRATE

MEBEVERINE 1.2 Antispasmodics and other drugs altering None HYDROCHLORIDE gut motility->Other antispasmodics

1.2 Antispasmodics and other drugs altering Mebeverine oral suspension has not been approved for prescribing. Mebeverine First line formulary gut motility->Other Hydrochloride choice antispasmodics->MEBEVERINE If a liquid preparation of an antispasmodic is required, use dicycloverine liquid HYDROCHLORIDE

1.2 Antispasmodics and other drugs altering First line formulary gut motility->Other Colofac® choice antispasmodics->MEBEVERINE HYDROCHLORIDE

1.2 Antispasmodics and other drugs altering Not approved for gut motility->Other Modified release prescribing antispasmodics->MEBEVERINE HYDROCHLORIDE

1.2 Antispasmodics and other drugs altering Not approved for gut motility->Other Colofac® MR prescribing antispasmodics->MEBEVERINE HYDROCHLORIDE->Modified release

1.2 Antispasmodics and other drugs altering Compound Not approved for gut motility->Other preparations prescribing antispasmodics->MEBEVERINE HYDROCHLORIDE 1.2 Antispasmodics and other drugs altering Not approved for gut motility->Other Fybogel® Mebeverine prescribing antispasmodics->MEBEVERINE HYDROCHLORIDE->Compound preparations

Joint formulary 1.2 Antispasmodics and other drugs altering PEPPERMINT OIL choice gut motility->Other antispasmodics

1.2 Antispasmodics and other drugs altering Joint formulary Colpermin® gut motility->Other choice antispasmodics->PEPPERMINT OIL

1.2 Antispasmodics and other drugs altering Joint formulary Mintec® gut motility->Other choice antispasmodics->PEPPERMINT OIL

Test for Helicobacter Hospital only 1.3 Antisecretory drugs and mucosal pylori prescribing protectants->Helicobacter pylori infection

1.3 Antisecretory drugs and mucosal Hospital only diabact UBT® protectants->Helicobacter pylori prescribing infection->Test for Helicobacter pylori

1.3 Antisecretory drugs and mucosal Helicobacter Test Hospital only protectants->Helicobacter pylori INFAI® prescribing infection->Test for Helicobacter pylori

1.3 Antisecretory drugs and mucosal Hospital only Pylobactell® protectants->Helicobacter pylori prescribing infection->Test for Helicobacter pylori

Not approved for 1.3 Antisecretory drugs and mucosal CIMETIDINE prescribing protectants->1.3.1 H2-receptor antagonists

1.3 Antisecretory drugs and mucosal Not approved for Cimetidine protectants->1.3.1 H2-receptor prescribing antagonists->CIMETIDINE

1.3 Antisecretory drugs and mucosal Not approved for Tagamet® protectants->1.3.1 H2-receptor prescribing antagonists->CIMETIDINE

Not approved for 1.3 Antisecretory drugs and mucosal FAMOTIDINE prescribing protectants->1.3.1 H2-receptor antagonists

1.3 Antisecretory drugs and mucosal Not approved for Famotidine protectants->1.3.1 H2-receptor prescribing antagonists->FAMOTIDINE Not approved for 1.3 Antisecretory drugs and mucosal NIZATIDINE prescribing protectants->1.3.1 H2-receptor antagonists

1.3 Antisecretory drugs and mucosal Not approved for Nizatidine protectants->1.3.1 H2-receptor prescribing antagonists->NIZATIDINE

Joint formulary 1.3 Antisecretory drugs and mucosal RANITIDINE Ranitidine injection should only be prescribed in secondary care by or under the explicit direction of a specialist. choice protectants->1.3.1 H2-receptor antagonists

1.3 Antisecretory drugs and mucosal Joint formulary Ranitidine protectants->1.3.1 H2-receptor Ranitidine injection should only be prescribed in secondary care by or under the explicit direction of a specialist. choice antagonists->RANITIDINE

1.3 Antisecretory drugs and mucosal Prescribe generically Not approved for Zantac® protectants->1.3.1 H2-receptor prescribing antagonists->RANITIDINE Ranitidine injection should only be prescribed in secondary care by or under the explicit direction of a specialist.

Selective Specialist 1.3 Antisecretory drugs and mucosal antimuscarinics knowledge drugs protectants

TRIPOTASSIUM Specialist 1.3 Antisecretory drugs and mucosal DICITRATOBISMUTHATE knowledge drugs protectants->1.3.3 Chelates and complexes

1.3 Antisecretory drugs and mucosal Specialist protectants->1.3.3 Chelates and De-Noltab® knowledge drugs complexes->TRIPOTASSIUM DICITRATOBISMUTHATE

Joint formulary 1.3 Antisecretory drugs and mucosal SUCRALFATE choice protectants->1.3.3 Chelates and complexes

1.3 Antisecretory drugs and mucosal Joint formulary Antepsin® protectants->1.3.3 Chelates and choice complexes->SUCRALFATE

Prostaglandin Hospital only 1.3 Antisecretory drugs and mucosal analogues prescribing protectants

Hospital only 1.3 Antisecretory drugs and mucosal Misoprostol is not routinely used for GI indications. MISOPROSTOL prescribing protectants->1.3.4 Prostaglandin analogues

1.3 Antisecretory drugs and mucosal Not approved for Cytotec® protectants->1.3.4 Prostaglandin prescribing analogues->MISOPROSTOL 1.3 Antisecretory drugs and mucosal With diclofenac or Not approved for protectants->1.3.4 Prostaglandin naproxen prescribing analogues->MISOPROSTOL

Joint formulary 1.3 Antisecretory drugs and mucosal ESOMEPRAZOLE IV esomeprazoleshould only be prescribed in secondary care by or under the explicit direction of a specialist. choice protectants->1.3.5 Proton pump inhibitors

1.3 Antisecretory drugs and mucosal Joint formulary Esomeprazole protectants->1.3.5 Proton pump IV esomeprazoleshould only be prescribed in secondary care by or under the explicit direction of a specialist. choice inhibitors->ESOMEPRAZOLE

1.3 Antisecretory drugs and mucosal Not approved for Nexium® protectants->1.3.5 Proton pump IV esomeprazoleshould only be prescribed in secondary care by or under the explicit direction of a specialist. prescribing inhibitors->ESOMEPRAZOLE

1.3 Antisecretory drugs and mucosal Not approved for With naproxen protectants->1.3.5 Proton pump prescribing inhibitors->ESOMEPRAZOLE

Joint formulary 1.3 Antisecretory drugs and mucosal LANSOPRAZOLE choice protectants->1.3.5 Proton pump inhibitors

1.3 Antisecretory drugs and mucosal Joint formulary Lansoprazole protectants->1.3.5 Proton pump choice inhibitors->LANSOPRAZOLE

1.3 Antisecretory drugs and mucosal Joint formulary Zoton® protectants->1.3.5 Proton pump Prescribe generically choice inhibitors->LANSOPRAZOLE

Joint formulary 1.3 Antisecretory drugs and mucosal OMEPRAZOLE Parenteralomeprazole has not been approved for prescribing. choice protectants->1.3.5 Proton pump inhibitors

1.3 Antisecretory drugs and mucosal Joint formulary Omeprazole protectants->1.3.5 Proton pump Parenteralomeprazole has not been approved for prescribing. choice inhibitors->OMEPRAZOLE

Parenteralomeprazole has not been approved for prescribing. 1.3 Antisecretory drugs and mucosal Not approved for Losec® protectants->1.3.5 Proton pump prescribing inhibitors->OMEPRAZOLE Prescribe generically

1.3 Antisecretory drugs and mucosal Not approved for With ketoprofen protectants->1.3.5 Proton pump prescribing inhibitors->OMEPRAZOLE

Joint formulary 1.3 Antisecretory drugs and mucosal PANTOPRAZOLE Parenteral pantoprazoleshould only be prescribed in secondary care by or under the explicit direction of a specialist. choice protectants->1.3.5 Proton pump inhibitors 1.3 Antisecretory drugs and mucosal Joint formulary Pantoprazole protectants->1.3.5 Proton pump Parenteral pantoprazoleshould only be prescribed in secondary care by or under the explicit direction of a specialist. choice inhibitors->PANTOPRAZOLE

1.3 Antisecretory drugs and mucosal Not approved for Protium® protectants->1.3.5 Proton pump Prescribe generically. prescribing inhibitors->PANTOPRAZOLE

Joint formulary 1.3 Antisecretory drugs and mucosal RABEPRAZOLE SODIUM choice protectants->1.3.5 Proton pump inhibitors

1.3 Antisecretory drugs and mucosal Joint formulary Rabeprazole protectants->1.3.5 Proton pump choice inhibitors->RABEPRAZOLE SODIUM

1.3 Antisecretory drugs and mucosal Not approved for Pariet® protectants->1.3.5 Proton pump prescribing inhibitors->RABEPRAZOLE SODIUM

Adsorbents and Not approved for 1.4 Acute diarrhoea bulk-forming drugs prescribing

Not approved for 1.4 Acute diarrhoea->1.4.1 Adsorbents and KAOLIN, LIGHT prescribing bulk-forming drugs

Not approved for 1.4 Acute diarrhoea->1.4.1 Adsorbents and Kaolin Mixture, BP prescribing bulk-forming drugs->KAOLIN, LIGHT

Joint formulary 1.4 Acute diarrhoea->1.4.2 Antimotility CODEINE PHOSPHATE choice drugs

Joint formulary 1.4 Acute diarrhoea->1.4.2 Antimotility Preparations choice drugs->CODEINE PHOSPHATE

Not approved for 1.4 Acute diarrhoea->1.4.2 Antimotility CO-PHENOTROPE prescribing drugs

Not approved for 1.4 Acute diarrhoea->1.4.2 Antimotility Co-phenotrope prescribing drugs->CO-PHENOTROPE

LOPERAMIDE Joint formulary 1.4 Acute diarrhoea->1.4.2 Antimotility HYDROCHLORIDE choice drugs

Joint formulary 1.4 Acute diarrhoea->1.4.2 Antimotility Loperamide choice drugs->LOPERAMIDE HYDROCHLORIDE

Joint formulary 1.4 Acute diarrhoea->1.4.2 Antimotility Imodium® choice drugs->LOPERAMIDE HYDROCHLORIDE Compound Not approved for 1.4 Acute diarrhoea->1.4.2 Antimotility preparations prescribing drugs->LOPERAMIDE HYDROCHLORIDE

1.4 Acute diarrhoea->1.4.2 Antimotility Not approved for Imodium® Plus drugs->LOPERAMIDE prescribing HYDROCHLORIDE->Compound preparations

Not approved for 1.4 Acute diarrhoea->1.4.2 Antimotility MORPHINE prescribing drugs

Kaolin and Morphine Not approved for 1.4 Acute diarrhoea->1.4.2 Antimotility Mixture, BP prescribing drugs->MORPHINE

Enkephalinase Not approved for 1.4 Acute diarrhoea inhibitors prescribing

Not approved for 1.4 Acute diarrhoea->1.4.3 Enkephalinase RACECADOTRIL prescribing inhibitors

Not approved for 1.4 Acute diarrhoea->1.4.3 Enkephalinase Hidrasec® prescribing inhibitors->RACECADOTRIL

1.5 Chronic bowel disorders->Short bowel TEDUGLUTIDE None syndrome

1.5 Chronic bowel disorders->Short bowel Revestive® None syndrome->TEDUGLUTIDE

Specialist 1.5 Chronic bowel disorders->1.5.1 BALSALAZIDE SODIUM knowledge drugs Aminosalicylates

Specialist 1.5 Chronic bowel disorders->1.5.1 Colazide® knowledge drugs Aminosalicylates->BALSALAZIDE SODIUM

1.5 Chronic bowel disorders->1.5.1 MESALAZINE None Aminosalicylates

Specialist 1.5 Chronic bowel disorders->1.5.1 Asacol® knowledge drugs Aminosalicylates->MESALAZINE

Specialist 1.5 Chronic bowel disorders->1.5.1 Asacol® MR knowledge drugs Aminosalicylates->MESALAZINE

Specialist 1.5 Chronic bowel disorders->1.5.1 Ipocol® knowledge drugs Aminosalicylates->MESALAZINE

Specialist 1.5 Chronic bowel disorders->1.5.1 Mezavant® XL knowledge drugs Aminosalicylates->MESALAZINE Specialist 1.5 Chronic bowel disorders->1.5.1 Octasa® knowledge drugs Aminosalicylates->MESALAZINE

Specialist 1.5 Chronic bowel disorders->1.5.1 Pentasa® Pentasa granules are not approved for prescribing. knowledge drugs Aminosalicylates->MESALAZINE

Not approved for 1.5 Chronic bowel disorders->1.5.1 Salofalk® prescribing Aminosalicylates->MESALAZINE

Hospital only 1.5 Chronic bowel disorders->1.5.1 OLSALAZINE SODIUM Approved for distal colitis only. prescribing Aminosalicylates

Hospital only 1.5 Chronic bowel disorders->1.5.1 Dipentum® Approved for distal colitis only. prescribing Aminosalicylates->OLSALAZINE SODIUM A Shared Care Guideline (SCG) may be available. Where it is, obtain guideline from secondary care and if happy to prescribe in accordance with the guidelines, take over the agreed responsibilities Shared care 1.5 Chronic bowel disorders->1.5.1 SULFASALAZINE including prescribing. guidelines Aminosalicylates Click here to access shared care guidelines .

A Shared Care Guideline (SCG) may be available. Where it is, obtain guideline from secondary care and if happy to prescribe in accordance with the guidelines, take over the agreed responsibilities Shared care 1.5 Chronic bowel disorders->1.5.1 Sulfasalazine including prescribing. guidelines Aminosalicylates->SULFASALAZINE Click here to access shared care guidelines .

A Shared Care Guideline (SCG) may be available. Where it is, obtain guideline from secondary care and if happy to prescribe in accordance with the guidelines, take over the agreed responsibilities Shared care 1.5 Chronic bowel disorders->1.5.1 Salazopyrin® including prescribing. guidelines Aminosalicylates->SULFASALAZINE Click here to access shared care guidelines .

BECLOMETASONE Not approved for 1.5 Chronic bowel disorders->1.5.2 DIPROPIONATE prescribing Corticosteroids

1.5 Chronic bowel disorders->1.5.2 Second-line option (after prednisolone tablets) for the treatment of mild or moderate ulcerative colitis in active phase Hospital only Clipper® Corticosteroids->BECLOMETASONE of left-sided or extensive UC, as add-on therapy to 5-ASA containing drugs in patients who are non-responders to prescribing DIPROPIONATE 5-ASA therapy. Full 4 week therapy cycle must be prescribed by secondary care.

Specialist 1.5 Chronic bowel disorders->1.5.2 BUDESONIDE knowledge drugs Corticosteroids Specialist 1.5 Chronic bowel disorders->1.5.2 Budenofalk® Prescribe generically. knowledge drugs Corticosteroids->BUDESONIDE

Not approved for 1.5 Chronic bowel disorders->1.5.2 Entocort® Prescribe generically. prescribing Corticosteroids->BUDESONIDE

Specialist 1.5 Chronic bowel disorders->1.5.2 HYDROCORTISONE knowledge drugs Corticosteroids

Specialist 1.5 Chronic bowel disorders->1.5.2 Colifoam® knowledge drugs Corticosteroids->HYDROCORTISONE

Joint formulary 1.5 Chronic bowel disorders->1.5.2 PREDNISOLONE choice Corticosteroids

Joint formulary 1.5 Chronic bowel disorders->1.5.2 Oral preparations choice Corticosteroids->PREDNISOLONE

Specialist 1.5 Chronic bowel disorders->1.5.2 Rectal preparations knowledge drugs Corticosteroids->PREDNISOLONE

1.5 Chronic bowel disorders->1.5.2 Joint formulary Prednisolone Corticosteroids->PREDNISOLONE->Rectal choice preparations

1.5 Chronic bowel disorders->1.5.2 Joint formulary Predsol® Corticosteroids->PREDNISOLONE->Rectal choice preparations A Shared Care Guideline (SCG) may be available. Where it is, obtain guideline from secondary care and if happy to prescribe in accordance with the guidelines, take over the agreed responsibilities including Shared care 1.5 Chronic bowel disorders->1.5.3 Drugs prescribing. AZATHIOPRINE guidelines affecting the immune response Click here to access shared care guidelines .

A Shared Care Guideline (SCG) may be available. Where it is, obtain guideline from secondary care and if happy to prescribe in accordance with the guidelines, take over the agreed responsibilities including 1.5 Chronic bowel disorders->1.5.3 Drugs Shared care prescribing. Preparations affecting the immune guidelines response->AZATHIOPRINE Click here to access shared care guidelines .

Hospital only 1.5 Chronic bowel disorders->1.5.3 Drugs CICLOSPORIN prescribing affecting the immune response 1.5 Chronic bowel disorders->1.5.3 Drugs Hospital only Preparations affecting the immune prescribing response->CICLOSPORIN Oral mercaptopurine for malignancyshould only be prescribed in secondary care by or under the explicit direction of a specialist.

A Shared Care Guideline (SCG) may be available. Where it is, obtain guideline from secondary care and if Shared care 1.5 Chronic bowel disorders->1.5.3 Drugs MERCAPTOPURINE happy to prescribe in accordance with the guidelines, take over the agreed responsibilities including guidelines affecting the immune response prescribing.

Click here to access shared care guidelines .

A Shared Care Guideline (SCG) may be available. Where it is, obtain guideline from secondary care and if 1.5 Chronic bowel disorders->1.5.3 Drugs happy to prescribe in accordance with the guidelines, take over the agreed responsibilities including Shared care Preparations affecting the immune prescribing. guidelines response->MERCAPTOPURINE Click here to access shared care guidelines

Hospital only 1.5 Chronic bowel disorders->1.5.3 Drugs Oral methotrexate for malignancyand parenteral methotrexate should only be prescribed in secondary care METHOTREXATE prescribing affecting the immune response by or under the explicit direction of a specialist.

1.5 Chronic bowel disorders->1.5.3 Drugs Hospital only Oral methotrexate for malignancyand parenteral methotrexate should only be prescribed in secondary care Preparations affecting the immune prescribing by or under the explicit direction of a specialist. response->METHOTREXATE

Hospital only 1.5 Chronic bowel disorders->1.5.3 Drugs Cytokine modulators prescribing affecting the immune response

1.5 Chronic bowel disorders->1.5.3 Drugs Hospital only ADALIMUMAB affecting the immune response->Cytokine TA329 http://www.nice.org.uk/TA329 prescribing modulators

1.5 Chronic bowel disorders->1.5.3 Drugs Hospital only ADALIMUMAB affecting the immune response->Cytokine TA187 http://www.nice.org.uk/TA187 prescribing modulators

1.5 Chronic bowel disorders->1.5.3 Drugs Hospital only Preparations affecting the immune response->Cytokine prescribing modulators->ADALIMUMAB 1.5 Chronic bowel disorders->1.5.3 Drugs Hospital only TA 140, Infliximab is not recommended for the treatment of subacute manifestations of moderate to severe active INFLIXIMAB affecting the immune response->Cytokine TA329 http://www.nice.org.uk/TA329 prescribing ulcerative colitis that would normally be managed in an outpatient setting. modulators

1.5 Chronic bowel disorders->1.5.3 Drugs Hospital only TA 140, Infliximab is not recommended for the treatment of subacute manifestations of moderate to severe active INFLIXIMAB affecting the immune response->Cytokine TA187 http://www.nice.org.uk/TA187 prescribing ulcerative colitis that would normally be managed in an outpatient setting. modulators

1.5 Chronic bowel disorders->1.5.3 Drugs Hospital only TA 140, Infliximab is not recommended for the treatment of subacute manifestations of moderate to severe active INFLIXIMAB affecting the immune response->Cytokine TA163 http://www.nice.org.uk/TA163 prescribing ulcerative colitis that would normally be managed in an outpatient setting. modulators

1.5 Chronic bowel disorders->1.5.3 Drugs Hospital only GOLIMUMAB affecting the immune response->Cytokine TA329 http://www.nice.org.uk/TA329 prescribing modulators

Hospital only 1.5 Chronic bowel disorders->1.5.3 Drugs Vedolizumab prescribing affecting the immune response

1.5 Chronic bowel disorders->1.5.3 Drugs Hospital only VEDOLIZUMAB affecting the immune TA352 http://www.nice.org.uk/TA352 prescribing response->Vedolizumab

1.5 Chronic bowel disorders->1.5.3 Drugs Hospital only Entyvio® affecting the immune prescribing response->Vedolizumab->VEDOLIZUMAB

Not approved for Food allergy 1.5 Chronic bowel disorders prescribing

SODIUM Not approved for 1.5 Chronic bowel disorders->1.5.4 Food CROMOGLICATE prescribing allergy

Not approved for 1.5 Chronic bowel disorders->1.5.4 Food Nalcrom® prescribing allergy->SODIUM CROMOGLICATE

Joint formulary ISPAGHULA HUSK 1.6 Laxatives->1.6.1 Bulk-forming laxatives choice

Joint formulary 1.6 Laxatives->1.6.1 Bulk-forming Fybogel® choice laxatives->ISPAGHULA HUSK

Joint formulary 1.6 Laxatives->1.6.1 Bulk-forming Ispagel Orange® choice laxatives->ISPAGHULA HUSK

Not approved for METHYLCELLULOSE 1.6 Laxatives->1.6.1 Bulk-forming laxatives prescribing Not approved for 1.6 Laxatives->1.6.1 Bulk-forming Celevac® prescribing laxatives->METHYLCELLULOSE

Not approved for STERCULIA 1.6 Laxatives->1.6.1 Bulk-forming laxatives prescribing

Not approved for 1.6 Laxatives->1.6.1 Bulk-forming Normacol® prescribing laxatives->STERCULIA

Not approved for 1.6 Laxatives->1.6.1 Bulk-forming Normacol Plus® prescribing laxatives->STERCULIA

Joint formulary BISACODYL 1.6 Laxatives->1.6.2 Stimulant laxatives choice

Joint formulary 1.6 Laxatives->1.6.2 Stimulant Bisacodyl choice laxatives->BISACODYL

Specialist DANTRON 1.6 Laxatives->1.6.2 Stimulant laxatives knowledge drugs

With poloxamer ‘188’ Specialist 1.6 Laxatives->1.6.2 Stimulant (as co-danthramer) knowledge drugs laxatives->DANTRON

1.6 Laxatives->1.6.2 Stimulant Specialist Co-danthramer laxatives->DANTRON->With poloxamer knowledge drugs �188� (as co-danthramer)

With docusate sodium Not approved for 1.6 Laxatives->1.6.2 Stimulant (as co-danthrusate) prescribing laxatives->DANTRON

1.6 Laxatives->1.6.2 Stimulant Not approved for Co-danthrusate laxatives->DANTRON->With docusate prescribing sodium (as co-danthrusate)

Joint formulary DOCUSATE SODIUM 1.6 Laxatives->1.6.2 Stimulant laxatives choice

Joint formulary 1.6 Laxatives->1.6.2 Stimulant Dioctyl® choice laxatives->DOCUSATE SODIUM

Joint formulary 1.6 Laxatives->1.6.2 Stimulant Docusol® choice laxatives->DOCUSATE SODIUM

Joint formulary 1.6 Laxatives->1.6.2 Stimulant Rectal preparations choice laxatives->DOCUSATE SODIUM 1.6 Laxatives->1.6.2 Stimulant Norgalax Not approved for laxatives->DOCUSATE SODIUM->Rectal Micro-enema® prescribing preparations

Joint formulary GLYCEROL 1.6 Laxatives->1.6.2 Stimulant laxatives choice

Glycerol Suppositories, Joint formulary 1.6 Laxatives->1.6.2 Stimulant BP choice laxatives->GLYCEROL

Joint formulary SENNA 1.6 Laxatives->1.6.2 Stimulant laxatives choice

Joint formulary 1.6 Laxatives->1.6.2 Stimulant Senna choice laxatives->SENNA

Not approved for 1.6 Laxatives->1.6.2 Stimulant Manevac® prescribing laxatives->SENNA

Joint formulary 1.6 Laxatives->1.6.2 Stimulant Senokot® choice laxatives->SENNA

Hospital only SODIUM PICOSULFATE 1.6 Laxatives->1.6.2 Stimulant laxatives prescribing

Hospital only 1.6 Laxatives->1.6.2 Stimulant Sodium Picosulfate prescribing laxatives->SODIUM PICOSULFATE

Bowel cleansing Not approved for 1.6 Laxatives->1.6.2 Stimulant preparations prescribing laxatives->SODIUM PICOSULFATE

Other stimulant Not approved for 1.6 Laxatives->1.6.2 Stimulant laxatives laxatives prescribing

Hospital only ARACHIS OIL 1.6 Laxatives->1.6.3 Faecal softeners prescribing

Hospital only 1.6 Laxatives->1.6.3 Faecal Arachis Oil Enema prescribing softeners->ARACHIS OIL

Not approved for LIQUID PARAFFIN 1.6 Laxatives->1.6.3 Faecal softeners prescribing

Liquid Paraffin Oral Not approved for 1.6 Laxatives->1.6.3 Faecal Emulsion, BP prescribing softeners->LIQUID PARAFFIN

Joint formulary LACTULOSE 1.6 Laxatives->1.6.4 Osmotic laxatives choice Joint formulary 1.6 Laxatives->1.6.4 Osmotic Lactulose choice laxatives->LACTULOSE

Joint formulary MACROGOLS 1.6 Laxatives->1.6.4 Osmotic laxatives choice

Macrogol Oral Powder, Joint formulary 1.6 Laxatives->1.6.4 Osmotic Compound choice laxatives->MACROGOLS

Joint formulary 1.6 Laxatives->1.6.4 Osmotic Movicol® choice laxatives->MACROGOLS

Not approved for 1.6 Laxatives->1.6.4 Osmotic Movicol®-Half prescribing laxatives->MACROGOLS

Joint formulary 1.6 Laxatives->1.6.4 Osmotic Movicol® Paediatric choice laxatives->MACROGOLS

MAGNESIUM SALTS None 1.6 Laxatives->1.6.4 Osmotic laxatives

Not approved for 1.6 Laxatives->1.6.4 Osmotic Magnesium hydroxide prescribing laxatives->MAGNESIUM SALTS

1.6 Laxatives->1.6.4 Osmotic Magnesium Hydroxide Not approved for laxatives->MAGNESIUM SALTS->Magnesium Mixture, BP prescribing hydroxide

Magnesium hydroxide Hospital only 1.6 Laxatives->1.6.4 Osmotic with liquid paraffin prescribing laxatives->MAGNESIUM SALTS

Liquid Paraffin and 1.6 Laxatives->1.6.4 Osmotic Hospital only Magnesium Hydroxide laxatives->MAGNESIUM SALTS->Magnesium prescribing Oral Emulsion, BP hydroxide with liquid paraffin

Not approved for 1.6 Laxatives->1.6.4 Osmotic Magnesium sulfate prescribing laxatives->MAGNESIUM SALTS

1.6 Laxatives->1.6.4 Osmotic Not approved for Magnesium Sulfate laxatives->MAGNESIUM SALTS->Magnesium prescribing sulfate

Bowel cleansing Not approved for 1.6 Laxatives->1.6.4 Osmotic preparations prescribing laxatives->MAGNESIUM SALTS

Specialist PHOSPHATES (RECTAL) 1.6 Laxatives->1.6.4 Osmotic laxatives knowledge drugs

Fleet® Ready-to-use Specialist 1.6 Laxatives->1.6.4 Osmotic Enema knowledge drugs laxatives->PHOSPHATES (RECTAL) Phosphates Enema BP Specialist 1.6 Laxatives->1.6.4 Osmotic Formula B knowledge drugs laxatives->PHOSPHATES (RECTAL)

SODIUM CITRATE None 1.6 Laxatives->1.6.4 Osmotic laxatives (RECTAL)

Micolette Not approved for 1.6 Laxatives->1.6.4 Osmotic Micro-enema® prescribing laxatives->SODIUM CITRATE (RECTAL)

Micralax Joint formulary 1.6 Laxatives->1.6.4 Osmotic Micro-enema® choice laxatives->SODIUM CITRATE (RECTAL)

Hospital only 1.6 Laxatives->1.6.4 Osmotic Relaxit Micro-enema® prescribing laxatives->SODIUM CITRATE (RECTAL)

Not approved for 1.6 Laxatives->1.6.5 Bowel cleansing MACROGOLS prescribing preparations

Hospital only 1.6 Laxatives->1.6.5 Bowel cleansing Klean-Prep® prescribing preparations->MACROGOLS

Hospital only 1.6 Laxatives->1.6.5 Bowel cleansing Moviprep® prescribing preparations->MACROGOLS

Not approved for 1.6 Laxatives->1.6.5 Bowel cleansing MAGNESIUM CITRATE prescribing preparations

Not approved for 1.6 Laxatives->1.6.5 Bowel cleansing Citramag® prescribing preparations->MAGNESIUM CITRATE

Not approved for 1.6 Laxatives->1.6.5 Bowel cleansing PHOSPHATES (ORAL) prescribing preparations

Not approved for 1.6 Laxatives->1.6.5 Bowel cleansing OsmoPrep® prescribing preparations->PHOSPHATES (ORAL)

Not approved for 1.6 Laxatives->1.6.5 Bowel cleansing Fleet Phospho-soda® prescribing preparations->PHOSPHATES (ORAL)

SODIUM PICOSULFATE Hospital only 1.6 Laxatives->1.6.5 Bowel cleansing WITH MAGNESIUM prescribing preparations CITRATE

1.6 Laxatives->1.6.5 Bowel cleansing Hospital only CitraFleet® preparations->SODIUM PICOSULFATE WITH prescribing MAGNESIUM CITRATE 1.6 Laxatives->1.6.5 Bowel cleansing Hospital only Picolax® preparations->SODIUM PICOSULFATE WITH prescribing MAGNESIUM CITRATE

Peripheral Hospital only opioid-receptor 1.6 Laxatives prescribing antagonists

METHYLNALTREXONE Hospital only 1.6 Laxatives->1.6.6 Peripheral BROMIDE prescribing opioid-receptor antagonists

1.6 Laxatives->1.6.6 Peripheral Hospital only opioid-receptor Relistor® prescribing antagonists->METHYLNALTREXONE BROMIDE

1.6 Laxatives->1.6.6 Peripheral NALOXEGOL None TA345 http://www.nice.org.uk/TA345 opioid-receptor antagonists

1.6 Laxatives->1.6.6 Peripheral Moventig® None opioid-receptor antagonists->NALOXEGOL

Joint formulary 1.6 Laxatives->1.6.7 Other drugs used in LINACLOTIDE choice constipation

Joint formulary 1.6 Laxatives->1.6.7 Other drugs used in Constella® choice constipation->LINACLOTIDE

Joint formulary 1.6 Laxatives->1.6.7 Other drugs used in LUBIPROSTONE TA318 http://www.nice.org.uk/TA318 choice constipation

Not approved for 1.6 Laxatives->1.6.7 Other drugs used in Amitiza® prescribing constipation->LUBIPROSTONE

Specialist 1.6 Laxatives->1.6.7 Other drugs used in PRUCALOPRIDE TA211 http://www.nice.org.uk/TA211 knowledge drugs constipation

Specialist 1.6 Laxatives->1.6.7 Other drugs used in Resolor® knowledge drugs constipation->PRUCALOPRIDE

1.7 Local preparations for anal and rectal Not approved for Anugesic-HC® disorders->1.7.2 Compound haemorrhoidal prescribing preparations with corticosteroids

1.7 Local preparations for anal and rectal Joint formulary Anusol-HC® disorders->1.7.2 Compound haemorrhoidal choice preparations with corticosteroids 1.7 Local preparations for anal and rectal Not approved for Perinal® disorders->1.7.2 Compound haemorrhoidal prescribing preparations with corticosteroids

1.7 Local preparations for anal and rectal Not approved for Proctofoam HC® disorders->1.7.2 Compound haemorrhoidal prescribing preparations with corticosteroids

1.7 Local preparations for anal and rectal Joint formulary Proctosedyl® disorders->1.7.2 Compound haemorrhoidal choice preparations with corticosteroids

1.7 Local preparations for anal and rectal Not approved for Scheriproct® disorders->1.7.2 Compound haemorrhoidal prescribing preparations with corticosteroids

1.7 Local preparations for anal and rectal Not approved for Ultraproct® disorders->1.7.2 Compound haemorrhoidal prescribing preparations with corticosteroids

1.7 Local preparations for anal and rectal Not approved for Uniroid-HC® disorders->1.7.2 Compound haemorrhoidal prescribing preparations with corticosteroids

1.7 Local preparations for anal and rectal Joint formulary Xyloproct® disorders->1.7.2 Compound haemorrhoidal choice preparations with corticosteroids

Not approved for 1.7 Local preparations for anal and rectal Rectal sclerosants prescribing disorders

Not approved for 1.7 Local preparations for anal and rectal PHENOL prescribing disorders->1.7.3 Rectal sclerosants

1.7 Local preparations for anal and rectal Oily Phenol Injection, Hospital only disorders->1.7.3 Rectal BP prescribing sclerosants->PHENOL

1.7 Local preparations for anal and rectal Joint formulary GLYCERYL TRINITRATE disorders->1.7.4 Management of anal choice fissures

1.7 Local preparations for anal and rectal Joint formulary Rectogesic® disorders->1.7.4 Management of anal choice fissures->GLYCERYL TRINITRATE 1.9 Drugs affecting intestinal CHOLIC ACID None secretions->1.9.1 Drugs affecting biliary composition and flow

1.9 Drugs affecting intestinal Orphacol® None secretions->1.9.1 Drugs affecting biliary composition and flow->CHOLIC ACID

1.9 Drugs affecting intestinal URSODEOXYCHOLIC Specialist secretions->1.9.1 Drugs affecting biliary ACID knowledge drugs composition and flow

1.9 Drugs affecting intestinal Specialist secretions->1.9.1 Drugs affecting biliary Ursodeoxycholic Acid knowledge drugs composition and flow->URSODEOXYCHOLIC ACID

1.9 Drugs affecting intestinal Specialist secretions->1.9.1 Drugs affecting biliary Destolit® knowledge drugs composition and flow->URSODEOXYCHOLIC ACID

1.9 Drugs affecting intestinal Specialist secretions->1.9.1 Drugs affecting biliary Ursofalk® knowledge drugs composition and flow->URSODEOXYCHOLIC ACID

1.9 Drugs affecting intestinal Specialist secretions->1.9.1 Drugs affecting biliary Ursogal® knowledge drugs composition and flow->URSODEOXYCHOLIC ACID

1.9 Drugs affecting intestinal Other preparations for Not approved for secretions->1.9.1 Drugs affecting biliary biliary disorders prescribing composition and flow

1.9 Drugs affecting intestinal Not approved for secretions->1.9.1 Drugs affecting biliary Rowachol® prescribing composition and flow->Other preparations for biliary disorders

Joint formulary Bile acid sequestrants 1.9 Drugs affecting intestinal secretions choice

Joint formulary 1.9 Drugs affecting intestinal COLESTYRAMINE choice secretions->1.9.2 Bile acid sequestrants 1.9 Drugs affecting intestinal Joint formulary Preparations secretions->1.9.2 Bile acid choice sequestrants->COLESTYRAMINE

Not approved for Aprotinin 1.9 Drugs affecting intestinal secretions prescribing

Specialist Pancreatin 1.9 Drugs affecting intestinal secretions knowledge drugs

Specialist 1.9 Drugs affecting intestinal PANCREATIN knowledge drugs secretions->1.9.4 Pancreatin

Specialist 1.9 Drugs affecting intestinal Creon® 10 000 knowledge drugs secretions->1.9.4 Pancreatin->PANCREATIN

Specialist 1.9 Drugs affecting intestinal Creon® Micro knowledge drugs secretions->1.9.4 Pancreatin->PANCREATIN

Specialist 1.9 Drugs affecting intestinal Pancrex® knowledge drugs secretions->1.9.4 Pancreatin->PANCREATIN

Specialist 1.9 Drugs affecting intestinal Pancrex V® knowledge drugs secretions->1.9.4 Pancreatin->PANCREATIN

Higher-strength Specialist 1.9 Drugs affecting intestinal preparations knowledge drugs secretions->1.9.4 Pancreatin->PANCREATIN

1.9 Drugs affecting intestinal Specialist secretions->1.9.4 Creon® 25000 knowledge drugs Pancreatin->PANCREATIN->Higher-strength preparations

1.9 Drugs affecting intestinal Specialist secretions->1.9.4 Creon® 40 000 knowledge drugs Pancreatin->PANCREATIN->Higher-strength preparations

1.9 Drugs affecting intestinal Specialist secretions->1.9.4 Nutrizym 22® knowledge drugs Pancreatin->PANCREATIN->Higher-strength preparations

1.9 Drugs affecting intestinal Specialist secretions->1.9.4 Pancrease HL® knowledge drugs Pancreatin->PANCREATIN->Higher-strength preparations